A multifunctional β-cyclodextrin-conjugate photodelivering nitric oxide with fluorescence reporting by Benkovics Gábor et al.
International Journal of Pharmaceutics 531 (2017) 614–620A multifunctional b-cyclodextrin-conjugate photodelivering nitric
oxide with fluorescence reporting
Gábor Benkovicsb,c,1, Marta Perez-Lloreta,1, Damien Afonsoa, András Darcsid,
Szabolcs Bénid, Éva Fenyvesib, Milo Malangab,*, Salvatore Sortinoa,*
a Laboratory of Photochemistry, Department of Drug Sciences, University of Catania, I-95125, Italy
bCycloLab, Cyclodextrin R&D Ltd, Illatos út 7, H-1097 Budapest, Hungary
cDepartment of Organic Chemistry, Faculty of Science, Charles University in Prague, Hlavová 8, 128 43 Prague 2, Czech Republic
dDepartment of Pharmacognosy, Semmelweis University, ÜllÅi út 26, H-1085, Hungary
A R T I C L E I N F O
Article history:
Received 25 March 2017
Received in revised form 9 May 2017
Accepted 10 May 2017
Available online 11 May 2017
Keywords:
Cyclodextrin
Nitric oxide
Singlet oxygen
Light
Fluorescence
A B S T R A C T
This contribution reports the design, synthesis and photochemical properties of a novel cationic, water
soluble, b-cyclodextrin (bCD) conjugate integrating an anthracene moiety and a nitroaniline derivative
within the primary side of the bCD scaffold. Photoinduced energy transfer between the anthracene and
the nitroaniline chromophores effectively suppresses the fluorescence of the anthracene unit. Excitation
with visible light triggers the release of nitric oxide (NO) from the nitroaniline chromophore,
accompanied to the concomitant revival of the anthracene fluorescence, which acts as an optical reporter
for detecting the amount of the NO released. Furthermore, the anthracene moiety photogenerates singlet
oxygen (1O2) sequentially to NO release. The conjugate is also able to accommodate hydrophobic guests
within the bCD cavity, as proven by using naphthalene as a model compound. In view of the key role NO
and 1O2 play as anticancer and antibacterial species, the present bCD derivative represents an intriguing
candidate for further studies in biopharmaceutical research addressed to multimodal therapeutic
applications.
© 2017 Elsevier B.V. All rights reserved.
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Cyclodextrins (CDs) have been greatly developed during the last
thirty years as carriers of “conventional” drugs (Davis and
Brewster, 2004; Loftsson and Douchene, 2007). However, the
use of CDs as suitable vehicles for photoactivable therapeutic
compounds has been only recently object of attention (Mazzaglia
et al., 2012). Due to their hydrophobic cavity, natural CDs can host a
variety of photosensitive agents by supramolecular interactions
(Bortolus and Monti, 1996; Monti and Sortino, 2002). Nevertheless,
in most cases, the low binding constants between unmodified CDs
and guest molecules represent a major drawback of these systems
as bio-carriers, making the modification of the CD structure strictly
necessary in view of actual applications (Mazzaglia et al., 2006).
Modification of the CDs molecular scaffold through functionaliza-
tion of the primary and/or secondary hydroxyl groups with* Corresponding authors.
E-mail addresses: malanga@cyclolab.hu (M. Malanga), ssortino@unict.it
(S. Sortino).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijpharm.2017.05.023
0378-5173/© 2017 Elsevier B.V. All rights reserved.suitable photoresponsive units allows to obtain multifunctional
nanocarriers with intriguing properties whilst, at the same time,
maintaining the macrocycle's capacity for guests encapsulation
(Mourtzis et al., 2007, 2008; Yannakopoulou et al., 2011).
Nitric oxide (NO) is a pleiotropic bioregulator of important
physiological and pathophysiological processes encompassing
neurotransmission, vasodilatation and hormone secretion in living
bodies (Ignarro, 2010). Besides, NO is an excellent sacrificial
antioxidant, anticancer and antibacterial agent (Ignarro, 2009).
This scenario has opened a fervent research activity devoted to
developing compounds able to release NO under physiological
conditions as potential pharmaceuticals to fight a variety of
diseases (Wang et al., 2002, 2005; Riccio and Schoenfisch, 2012;
Seabra and Durán, 2010). However, the biological effects of NO are
strictly depending on its concentration, location and dose (Jia et al.,
2002). This has made the light-activated NO donors very appealing
due to the superb spatiotemporal accuracy the light triggering
offers (Ford, 2008; Sortino, 2010; Fry and Mascharak, 2011; Ford,
2013). Several NO photodonors (NOPD) have been supramolecu-
larly combined with CDs derivatives (Fraix et al., 2016). In contrast,
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CDs are reported to date (Piras et al., 2013).
Quantification of the NO delivery in real time is another
important issue to be faced, especially when the main interest is to
reach a critical molecule concentration to induce a specific effect. A
suitable way to address this quantification task is based on the use
of a fluorescent reporter. This elegant strategy relies on the
simultaneous photorelease of the desired bioactive species, i.e.
NO, and a fluorescent component (the reporter) from the same
nonfluorescent precursor (Veldhuyzen et al., 2003; Pellois et al.,
2004; Weinstain et al., 2010). The release process can be thus easily
quantified by monitoring the fluorescence emission of the reporter,
which acts exactly as an optical counter of the bioactive species.
Recently, we have reported interesting properties of an ad-hoc
designed molecular conjugate integrating two chromogenic
centers within the same covalent skeleton (Vittorino et al.,
2011; Kirejev et al., 2014), an anthracene moiety and a nitroaniline
derivative, this latter as a suitable NOPD (Caruso et al., 2007) In this
compound, the typical emission of the anthracene fluorophore is
completely suppressed by a photoinduced energy transfer to the
nitroaniline moiety. We demonstrated that the photorelease of NO
leads to the revival of the fluorescence of anthracene fluorophore
which acts as a fluorescent reporter for the NO delivery in living cells
(Vittorino et al., 2011; Kirejev et al., 2014).
Based on the above scenario we considered it of value to
translate this NO photorelease with fluorescent reporting concept
in a novel conjugate, which covalently integrates the NO photo-
releaser and the anthracene moiety within the same positively
charged bCD scaffold. This contribution reports the synthesis,
characterization and photochemical properties of the cationic bCD
conjugate AN-bCD-NOPD and the suitable model compounds AN-
bCD and bCD-NOPD (Fig. 1).
2. Experimental
2.1. Chemicals
6-Monodeoxy-6-monoazido-bCD and 6-monotosyl-bCD are
fine chemical products of CycloLab, 1,3-diaminopropanol (99%),
4-nitro-3-(trifluoromethyl)aniline (98%), glycidyltrimethylammo-
nium chloride (technical grade, 90%), sodium azide
(ReagentPlus1, 99.5%), hydrazine monohydrate (reagent grade,
98%), sodium borohydride (98.0%), anthracene-9-Fig. 1. Schematic of the multifunctional bCD conjugate AN-bCD-carboxaldehyde (97.0%), p-toluenesulfonyl chloride
(ReagentPlus1, 99%), trimethylamine (99%), 1,3-propanedithiol
(99%), palladium on carbon (5%), were sourced from Sigma–
Aldrich.
Dimethyl sulfoxide, formic acid, methanol, pyridine were
obtained from Molar Chemicals.
2.2. Instrumentation
1H, 13C NMR spectra and DEPT-ed-HSQC spectra were recorded
in DMSO-d6 or D2O (10 mg dissolved in 0.8 mL of deuterated
solvent) on a Varian DDR-600 spectrometer at 600 MHz at 298 K.
Mass spectra were obtained on Bruker ESQUIRE 3000 ES-ion
trap instrument with electrospray ionization (ESI) in negative
mode. All samples were dissolved in water.
Preparative chromatographic separations were performed on a
Büchi preparative chromatography system using SiliCycle Silica
Cartridge (4 cm  15 cm) packed with Lichroprep (120 g) RP-18
Phase (40–63 mm) as a stationary phase and water-methanol
gradient elution. The chromatographic station was equipped with
Büchi UV Photometer C-635 as a detector (detection wavelength
set at 390 nm for NOPD appended derivatives and at 245 nm for the
tosylated intermediate).
UV–vis absorption and fluorescence spectra were recorded with
a Jasco V 650 spectrophotometer and a Fluorolog-2 (Model, F111)
spectrofluorimeter, respectively. Fluorescence lifetimes were
recorded with the same spectrofluorimeter equipped with a
TCSPC Triple Illuminator. The samples were irradiated by a pulsed
diode excitation source Nanoled at 370 nm. The kinetic was
monitored at 420 nm and each solution itself was used to register
the prompt at 370 nm. The system allowed measurement of
fluorescence lifetimes from 200 ps. The multiexponential fit of the
fluorescence decay was obtained using the following equations: I
(t) = A1exp(t/t1) + A2exp(t/t2) (for the biexponential fit) and I
(t) = A1exp(t/t1) + A2exp(t/t2) + A3exp(t/t3) (for the triexpo-
nential fit). Multiexponential fitting were used because they gave
much better chi-square values than monoexponential fitting.
1O2 emission was registered with the same spectrofluorimeter
as above equipped with a NIR-sensitive liquid nitrogen cooled
photomultiplier, exciting the air-equilibrated samples in D2O
solution at 380 nm with the fluorimeter lamp.
Photolysis of the samples in solution was performed in a
thermostated quartz cell (1 cm pathlength, 3 mL capacity) underNOPD and the model compounds AN-bCD and bCD-NOPD.
Scheme 1. Reaction scheme for the synthesis of AN-bCD.
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100 mW) having a beam diameter of ca. 1.5 mm.
NO release was measured with a World Precision Instrument,
ISO-NO meter, equipped with a data acquisition system, and based
on direct amperometric detection of NO with short response time
(<5 s) and sensitivity range 1 nM–20 mM. The analog signal was
digitalized with a four-channel recording system and transferred
to a PC. The sensor was accurately calibrated by mixing standardScheme 2. Reaction scheme for solutions of NaNO2 with 0.1 M H2SO4 and 0.1 M KI according to the
reaction:
4H+ + 2I + 2NO2! 2H2O + 2NO + I2
Irradiation was performed in a thermostated quartz cell (1 cm
path length, 3 mL capacity) under gentle stirring by using the same
405 nm laser sources described above. NO measurements were
carried out with the electrode positioned outside the light path inthe synthesis of bCD-NOPD.
Scheme 3. Reaction scheme for the synthesis of AN-bCD-NOPD.
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the ISO-NO electrode.
3. Results and discussion
3.1. Syntheses
The model compound AN-bCD was synthesized according to
the procedure illustrated in Scheme 1 and briefly described in the
following (the full details are reported in the Supporting
Information).
6-Monotosyl-bCD was promptly converted to the amino-
analog 1 by exhaustive reduction of the intermediate 6-mono-
deoxy-6-monoazido bCD, according to literature (Jicsinszky and
Iványi, 2001). The amino group, located on the primary rim of CD
scaffold, is a suitable anchoring point for the introduction of the
anthracene chromophore. As compound 1 is obtained as free base,
the coupling could be achieved by a nucleophilic substitution in
DMF with the commercially available 9-(chloromethyl)anthra-
cene. This reaction setting was explored, but the conversion rate
was not satisfactory (30% formation of compound 2) and N-
dialkylated product (CD scaffold containing two anthracene
moieties) was considerably formed under the tested experimental
conditions (10%). Although chromatographic purification of the
crude can be attempted, the procedure is time-consuming, noteffective and resulted in low-yield. As efficient alternative for the
preparation of compound (2) a two-steps one-pot reaction based
on imine-reduction, allowing good conversion rate and avoiding
chromatographic purification, was applied. The addition of silica
gel to the reaction mixture during the first step was a fundamental
requirement for achieving quantitative conversion to the imine
intermediate 1a. The nano-porous material was effective in
removing the water accumulated during the condensation process
thus making convenient the coupling reaction. The second step
based on the mild reducing agent sodium borohydride proceeded
quantitatively within expectations. The introduction of the
permanent charges on the CD scaffolds was achieved by using
the alkylating agent, glycidyltrimethylammonium chloride, as
reaction solvent. This approach has the advantages of minimizing
the by-products formation and reducing the work-up to simple
fractional crystallization cycles.
The model compound bCD-NOPD was synthesized according
to the procedure illustrated in Scheme 2 and briefly described in
the following (the full details are reported in the Supporting
Information).
The flexible linker, 1,3-diaminopropane, was effectively intro-
duced on the CD scaffold by nucleophilic substitution on the 6-
monotosyl-bCD. In order to reduce the formation of by-products
such as CD dimers (two or more CD units connected through the
linker) and 3,6-anhydro derivatives, 1,3-diaminopropane was used
Fig. 2. (A) Absorption spectra of 40 mM aqueous solution AN-bCD-NOPD (a) and
the model compounds AN-bCD (b) and bCD-NOPD (c). (B) Fluorescence emission
spectra (lexc = 370 nm) of the model compound AN-bCD (d) and AN-bCD-NOPD
(e).
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portion-wise to the warm solvent solution. These precautions
ensured that 6-monotosyl-bCD was always acting as limiting
reagent and promptly converted to 6-monodeoxy-6-mono-(3-
aminopropylamino) bCD. The large excess of 1,3-diaminopropane
in combination with an adequate work-up (evaporation under
reduced pressure and precipitation with methanol-diisopropyl
ether mixture) also maintained compound 3 in free base form. This
is a strict requirement to successfully accomplish the following
reaction step as no extra base can be added to the reaction mixture
due to the high reactivity of 4-chloro-1-nitro-2-(trifluoromethyl)
benzene toward these species. It is worth to mention that the
decision of attaching the NOPD moiety to the CD scaffold through aFig. 3. NO release profile observed for optically matched aqueous solutions of AN-
bCD-NOPD (a) and bCD-NOPD (b) upon irradiation with lexc = 405 nm at 25 C.linker, was the result of several unsuccessful attempts to directly
introduce the chromophore on the CD rim. No adequate reaction
conditions were found to react the reagent 4-chloro-1-nitro-2-
(trifluoromethyl)benzene with the free base of 6-monoamino-6-
monodeoxy-bCD. The most probable reason is that the nitroben-
zene derivative formed a strong inclusion complex with the bCD
cavity locating the chlorine atom on the secondary side (Ueno and
Breslow, 1982). The establishment of this supramolecular interac-
tion precludes primary-side substitution.
Compound 4 was obtained in moderate yield by reacting the
free base of compound 3 with 4-chloro-1-nitro-2-(trifluoromethyl)
benzene. As no extra base could be added to the reaction mixture
without consuming the chromophore, the product was formed
only at around 40% conversion rate. Reversed-phase chro-
matographic purification was needed to separate the unreacted
compound 3 from the target product. The solubility profile of
compound 4 was improved by modifying some of the hydroxyl
groups with permanently charged side-chains.
The multifunctional conjugate AN-bCD-NOPD was synthesized
according to the procedure illustrated in Scheme 3 and briefly
described in the following (the full details are reported in the
Supporting Information). In order to introduce both the chromo-
phores on the primary side of the CD scaffold, tosylation of 6-
monoazido-6-monodeoxy-bCD was performed in pyridine. This
approach is selective for the modification of the primary rim of the
macrocycle (Matsui et al., 1976) and generates a mixture of three
pairs of pseudoenantiomers (6A-monodeoxy-6A-monoazido-6X-
monotosyl-b-CD, compound 5). The mixture of primary-side
hetero-disubstituted bCD was isolated by preparative reversed-
phase chromatography. The strategy developed for the introduc-
tion of the NOPD chromophore in model compound bCD-NOPD
was applied at this stage almost without modifications. The azido
moiety remained unaltered both in harsh alkaline conditions
(preparation of compound 6) and during the prolonged heating
required for the nitrobenzene installation (preparation of com-
pound 7). The most challenging part of the synthetic work was the
introduction of the anthracene fluorophore on the NOPD-
appended CD. A three-step one-pot reaction was carefully
designed to fulfill all the necessary requirements. First, a mild
reduction method was chosen for the selective reduction of azido
group in the presence of the aromatic nitro group. This approach
was based on the use of 1,3-propanedithiol and trimethylamine as
reduction mixture to obtain the amino-intermediate 7a. Addition
of anthracene-9-carboxaldehyde and heating of the reaction
mixture resulted in almost complete conversion (90% conversion
rate based on TLC estimation) to anthracene-appended imine-
intermediate 7b. Portion-wise addition of NaBH4 and prolonged
stirring at room temperature afforded anthracene-appended
amine-intermediate, compound 8, in quantitative conversion.
Preparative reversed-phase chromatographic purification allowed
the removal of the unreacted compound 7a and the isolation of
targeted compound 8. As the CD scaffold is modified simulta-
neously with two aromatic units, its solubility in aqueous
environment is limited. This drawback was overcome by introduc-
ing quaternary ammonium bearing moieties in the system,
obtaining the desired compound AN-bCD-NOPD.
3.2. Spectroscopic properties and photochemical behavior
All compounds synthesized are well soluble in aqueous
medium due to the presence of the cationic termination mainly
located at the secondary rim of the bCD scaffold. The absorption
spectrum of AN-bCD-NOPD (a in Fig. 1A) exhibits the distinctive
spectral features of the anthracene chromophore below 400 nm
and an intense absorption at longer wavelengths extending beyond
450 nm, due to the contribution of the nitroaniline moiety. This
Fig. 4. (A) Fluorescence (lexc = 370 nm) spectral changes observed upon irradiation
of an aqueous solution of AN-bCD-NOPD (40 mM) at regular irradiation times of
5 min (from bottom to top) with visible light (lexc = 405 nm). The inset shows the
fluorescence decay and the related multiexponential fitting for solutions of AN-
bCD-NOPD (a), the model compound AN-bCD (b) and AN-bCD-NOPD after 45 min
irradiation with visible light (c); lexc = 370 nm; lem = 420 nm. (B) Correlation of the
fluorescence increase observed in Fig. 4A and the concentration of NO released from
the same solution (I and I0 represent the fluorescence intensities at 420 nm after
each irradiation time and that of the non-irradiated solution, respectively).
Fig. 6. Absorption spectra of an aqueous solution of AN-bCD-NOPD (30 mM) (a)
and its complex with naphthalene (b) (left Y-axis). Fluorescence emission spectrum
(c) observed upon excitation at lexc = 280 nm of the sample b (right Y-axis).
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independent model compound AN-bCD and bCD-NOPD (b and c
in Fig. 2A), ruling out any significant interaction between the
anthracene and nitroaniline chromophores in the ground state. On
the other hand, the intense fluorescence emission of the
anthracene fluorophore observed in the case of AN-bCD (d in
Fig. 2) is significantly quenched in the bichromophoric conjugateFig. 5. Luminescence spectra detected upon 370 nm light excitation of a D2O
solutions of AN-bCD-NOPD (40 mM) before (&) and after (*) 1 h irradiation at
lexc = 405 nm.AN-bCD-NOPD (e in Fig. 2B), suggesting a remarkable interaction
between the two chromophores in the excited state. According to
what already demonstrated in our previous studies (Vittorino
et al., 2011; Kirejev et al., 2014), this drastic fluorescence quenching
can be explained on the basis of a photoinduced energy transfer
between the anthracene fluorophore and the nitroaniline compo-
nents in the conjugate, which is encouraged by the close proximity
of the donor and acceptor, both linked at the same rim.
The capability of AN-bCD-NOPD to deliver NO under light
stimuli was investigated by the direct and real-time monitoring of
this transient species using an ultrasensitive NO electrode which
directly reveals NO with nM concentration sensitivity by an
amperometric technique (Coneski and Schoenfisch, 2012). The
absorption spectral features of AN-bCD-NOPD allow the selective
excitation of the NO photoreleaser component of the conjugate at
lexc > 400 nm. The results illustrated in Fig. 3 provide unambiguous
evidence that the bichromophoric CD conjugate is very stable in
the dark but supplies NO upon illumination with lexc = 405 nm.
Note that, the rate of photorelease is very similar to that observed
for an optically matched solution of the model compound bCD-
NOPD.
NO photorelease from AN-bCD-NOPD is accompanied by
dramatic revival of the characteristic emission arising from the
anthracene fluorophore. Fig. 4A shows the fluorescence emission
spectra observed at regular irradiation times with visible light up
to 45 min. This fluorescence restoring is due to the formation of a
reaction product formed after the loss of NO that, in contrast to the
nitroaniline derivative, is not a good energy acceptor and thus is
not able to quench the fluorescence of the anthracene fluorophore.
This behavior also reflects in the dynamic of the emission. As
shown in the inset in Fig. 4A, the fluorescence decay of AN-bCD-
NOPD (trace a) was shorter than that of the model compound AN-
bCD (trace b). However, after 45 min irradiation of the AN-bCD-
NOPD solution, the fluorescence dynamic become slower (trace c),
according to the revival of the fluorescence. In such a way, the
anthracene unit represents an excellent optical reporter for the NO
release. In fact, as illustrated in Fig. 4B, we found an excellent linear
correlation between the concentration of NO photogenerated and
the increase of the fluorescence intensity of the optical reporter.
Note that, the suppression of the quenching of the excited state
of anthracene after NO release reflects also in the capability of this
component to photosensitize the formation of singlet oxygen
(1O2), the key species in photodynamic therapy of cancer and
bacterial diseases (Hasan et al., 2000). This was directly
demonstrated by direct detection through monitoring of the
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(Wilkinson et al., 1993). Fig. 5 shows that excitation of AN-bCD-
NOPD at lexc = 370 nm does not lead to any detectable formation of
1O2, according to effective quenching occurring of the anthracene
by the nitroaniline component. On the other hand, excitation at the
same wavelength after irradiating the AN-bCD-NOPD solution for
1 h at 405 nm, leads to the appearance of the characteristic
luminescence signals of 1O2 with maximum at ca. 1270 (Fig. 5).
Despite the covalent linking with the two chromophores, the
CD cavity of AN-bCD-NOPD is still able to accommodate
hydrophobic guests. This was proven by using naphthalene as a
model compound, which is insoluble in water medium. To this end,
a methanol solution of naphthalene was prepared. After drying the
solvent, the resulting dried sample was added of an aqueous
solution of AN-bCD-NOPD and the sample was stirred for 1 h at
room temperature. The mixture was then filtered and analyzed by
UV-Vis absorption. Fig. 6 shows the spectroscopic properties of
AN-bCD-NOPD before the addition to the film sample (a) and after
the filtration procedure (b). The presence of the typical structured
absorption bands of the naphthalene at ca. 275 and 285 nm (b)
provides unambiguous evidence for the encapsulation of the
guests within the CD cavity. Besides, the characteristic fluores-
cence emission of naphthalene (c in Fig. 6) further confirms the
effective formation of the host-guest supramolecular complex.
4. Conclusions
We have devised and synthesized a novel multifunctional CD
conjugate, bearing a nitroaniline and an anthracene chromophoric
unit, able to incorporate a number of functionalities within the
same molecular skeleton. AN-bCD-NOPD is well soluble in water
due to the cationic appendages present mainly at the lower rim of
the CD scaffold and is able to deliver NO under the exclusive control
of visible light stimuli. NO photorelease restores the fluorescence
of the anthracene fluorophore, which acts as an optical reporter of
NO concentration. To the best of our knowledge, this represents the
first example of NO photodispenser with fluorescence reporting
integrated in a CD scaffold. Furthermore, we have demonstrated
that the anthracene component is also capable to photogenerate
1O2 sequentially to the NO release. The AN-bCD-NOPD conjugate
is also able to accommodate hydrophobic guests within the bCD
cavity, as proven by using naphthalene as a model compound. In
view of the key role NO and 1O2 plays in photodynamic therapy,
this bCD derivative represents an intriguing candidate for
biopharmaceutical research. Studies in this direction are currently
underway in our laboratories.
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